2023-505889-29-01RecruitingPhase 2
Trial evaluating the efficacy and the safety of FOLFIRINOX3 treatment in patients with unresectable locally advanced or metastatic pancreatic cancer in first line of chemotherapy
Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 20 Jul 2023
- Start date
- 1 Feb 2024
- Lead sponsor
- Centr Georges Francois Leclerc
- Diseases
- Pancreatic cancer
- EU CT number
- 2023-505889-29-01
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 90
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Besancon University Hospital Center | Besancon Cedex | France | Recruiting |
| Hopital Prive Sainte Marie Chalon | Chalon Sur Saone | France | Recruiting |
| Centr Georges Francois Leclerc | Dijon | France | Recruiting |
| Institut Godinot | Reims | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.